A potential risk associated with a widely-used diabetes and weight loss medication has emerged. Recent research links semaglutide, marketed as Ozempic and Wegovy, with a rare vision condition. Notably, the study indicates an increased likelihood of nonarteritic anterior ischemic optic neuropathy (NAION) among users. This article delves into the newly discovered risks of semaglutide, highlighting
